PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(11): e14082.
Published online 2010 November 29. doi:  10.1371/journal.pone.0014082
PMCID: PMC2993930

Epithelial Cell Transforming Sequence 2 in Human Oral Cancer

Jörg Hoheisel, Editor

Abstract

Background

Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor for Rho family GTPase, which has been implicated in the malignant phenotype of human cancers. Little is known about the effect of a high level of ECT2 in regulating oral cancer cell behavior. In this study, we investigated the involvement of ECT2 in oral squamous cell carcinoma (OSCC).

Methodology/Principal Findings

We analyzed ECT2 expression in OSCC-derived cell lines and primary OSCCs compared with matched normal tissue (n = 96) by quantitative reverse transcriptase-polymerase chain reaction, Western blot, and immunohistochemistry. We then evaluated the correlation between the ECT2 expression status in primary OSCCs and the clinicopathological features. ECT2 expression was significantly up-regulated in OSCCs in vitro and in vivo (p<0.05). Among the clinical variables analyzed, higher ECT2 expression also was associated with the TNM stage grading (p<0.05). When we performed functional analyses of ECT2 in OSCC-derived cells using the shRNA system, the cellular proliferation of the ECT2 knockdown cells decreased significantly compared with the control cells (p<0.05). Cell cycle analysis by flow cytometry showed arrest of cell cycle progression at the G1 phase in the ECT2 knockdown cells. We also found up-regulation of the Cip/Kip family of the cyclin-dependent kinase inhibitors, p21cip1 and p27kip1, and down-regulation of cyclin D1, cyclin E, and CDK4. These data suggested that the elevated Cip/Kip family induced inhibition of the cyclin D1-CDK complex activity leading to cell cycle arrest at the G1 phase.

Conclusions/Significance

Our results proposed for the first time that ECT2 is an indicator of cellular proliferation in OSCCs and that ECT2 might be a potential therapeutic target for the development of new treatments for OSCCs.

Introduction

Oral squamous cell carcinoma (OSCC) is a major cause of morbidity and mortality globally, accounting for 275,000 new cases and more than 120,000 deaths annually [1]. Many risk factors have been identified, including tobacco and alcohol use [2], [3], [4]. However, some patients develop OSCC without risk factors, suggesting that host susceptibility plays an important role. Molecular changes in a number of oncogenes and tumor suppressor genes associated with the development of OSCC could be important clues to preventing this disease [4], [5].

Microarray technology has been helpful for analyzing changes in thousands of genes and identifying significant patterns. We previously reported gene expression profiling of OSCC to identify cancer-related genes [6]. Among the genes, epithelial cell transforming sequence 2 (ECT2) was significantly up-regulated in OSCC. ECT2 is a guanine nucleotide exchange factor (GEF) for Rho family GTPase related to cytokinesis [7], [8], [9], [10], [11]. GEFs catalyze the exchange of GDP for GTP, thereby activating the Rho GTPases in signal transduction. ECT2 expression is dynamically controlled throughout the cell cycle. Upon breakdown of the nuclear envelope during mitosis, ECT2 is dispersed throughout the cytoplasm, then ECT2 becomes localized to the mitotic spindles during metaphase, the cleavage furrow during telophase, and the mid-body at the end of cytokinesis [8]. The Rho GTPases have been implicated in the malignant phenotype of human cancers as a result of their participation in aberrant signaling in tumor cells [12], [13], [14], [15], [16], [17].

In the current study, ECT2 was frequently overexpressed in OSCC-derived cell lines and primary OSCCs. In addition, a shRNA experiment showed that ECT2 down-regulation resulted in decreased cellular proliferation by cell cycle arrest of the G1 phase. Therefore, we suggested that ECT2 might be a biomarker of proliferation and potential therapeutic target for OSCCs.

Results

Evaluation of ECT2 mRNA expression in OSCC-derived cell lines

To investigate mRNA expression of ECT2 identified as a cancer-related gene by our microarray analysis [6], we performed quantitative reverse transcriptase PCR (qRT-PCR) analysis using six OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, H1, Ca9-22, and Sa3) and human normal oral keratinocytes (HNOKs). mRNA expression levels were normalized to GAPDH. ECT2 mRNA was significantly up-regulated in all OSCC cell lines compared with the HNOKs (Figure 1A, *p<0.05).

Figure 1
ECT2 exprssion in OSCC-derived cell lines.

Evaluation of ECT2 protein expression in OSCC-derived cell lines

We performed Western blot analysis to investigate ECT2 protein expression status in the OSCC-derived cell lines and the HNOKs (Figure 1B). The molecular weight of the ECT2 was 112 kDa. A significant increase in ECT2 protein expression was observed in all OSCC cell lines compared with the HNOKs. Expression analysis indicated that both transcription and translation products of this molecule were highly expressed in OSCC-derived cell lines.

Evaluation of ECT2 expression in primary OSCCs

We measured the ECT2 mRNA expression levels in primary OSCCs and paired normal oral tissues from 96 patients. Similar to the data from the OSCC-derived cell lines, qRT-PCR analysis showed that ECT2 mRNA expression was up-regulated in 75 (78%) of 96 primary OSCCs compared with the matched normal oral tissues. The relative mRNA expression levels in the normal oral tissues and primary OSCCs ranged from 0.003 to 1.632 (median, 0.081) and 0.005 to 4.39 (median, 0.289), respectively (Figure 2, p<0.05).

Figure 2
Comparison of ECT2 mRNA expression levels between primary OSCCs and matched normal oral tissues.

We then analyzed ECT2 protein expression by immunohistochemistry (IHC). Representative IHC results for ECT2 protein in normal oral tissue and primary OSCC are shown in Figure 3A and B. Positive immunoreaction for ECT2 was detected in the nucleus and cytoplasm. Strong ECT2 immunoreactions were detected in OSCCs, whereas normal oral tissues showed negative immunostaining. The ECT2 IHC scores of normal oral tissues and OSCCs ranged from 8.33 to 85.33 (median, 44.00) and 55.67 to 211.33 (median, 163.33), respectively. The ECT2 IHC scores in primary OSCCs were significantly higher than those in normal tissues (Figure 3C, p<0.001). The correlations between the clinicopathologic characteristics of the patients with OSCC and the status of ECT2 protein expression using the IHC scoring system are shown in Table 1. Among the clinical classifications, ECT2-positive OSCCs were correlated with tumor size (p = 0.043) and TNM staging of OSCC (p = 0.044) (Table 1).

Figure 3
Evaluation of ECT2 protein expression in primary OSCCs.
Table 1
Correlation between ECT2 expression and clinical classification in OSCCs.

Establishment of ECT2 knockdown cells

To obtain stable ECT2 knockdown transfectants, we used the ECT2 shRNA (shECT2) plasmid and the control shRNA (Mock) plasmid. To assess ECT2 mRNA and protein expression in shECT2-transfected cells, we performed qRT-PCR and Western blot analyses. Figure 4A shows that the ECT2 mRNA expression in shECT2-transfected cells was significantly lower than in Mock-transfected cells. ECT2 protein levels in shECT2-transfected cells also decreased markedly compared with Mock-transfected cells (Figure 4B). ECT2 protein expression levels were consistent with the mRNA expression in the transfectants.

Figure 4
Expression ECT2 in shECT2-transfected cells.

Reduced cellular growth in ECT2 knockdown cells

To investigate the antiproliferative effects in shECT2-transfected cells, cellular growth was monitored for 7 days. The shECT2-transfected cells showed a significant decrease in cellular growth compared with Mock-transfected cells (Figure 5).

Figure 5
Proliferation of shECT2-transfected cells.

Knockdown of ECT2 promotes cell cycle arrest

To investigate the mechanism by which ECT2 is related to cell cycle progression, we performed FACS analysis of shECT2-transfected cells. The percentage of the G1 phase in shECT2-transfected cells was significantly higher than in Mock-transfected cells (Figure 6A, p<0.05), suggesting that down-regulation of ECT2 inhibited cellular proliferation by induction of G1 arrest. To identify the mechanism by which ECT2 blocks G1 progression, we assessed the expression level of cyclin-dependent kinase inhibitors (p16INK4A, p21cip1, p27kip1), cyclin D1, cyclin E, and CDK4 (Figure 6B). PCR data showed up-regulation of p21cip1 and p27kip1 and down-regulation of cyclin D1, cyclin E, and CDK4 in shECT2-transfected cells.

Figure 6
shECT2 promotes G1 arrest.

Discussion

Our previous microarray data [6] showed significant up-regulation of ECT2 in OSCC-derived cell lines. In the present study, ECT2 mRNA and protein were highly expressed in vitro and in vivo in OSCC. Regional copy number of 3q26 increases in several cancers, such as head and neck, lung, and cervix [18], [19]. This region has cancer-related genes (PRKC1 and SOX2) as well as ECT2. Therefore, genomic unbalance would be the reason of ECT2 overexpression in OSCC. The ECT2 protein expression levels in primary OSCCs were correlated with the TNM stage grading (Table 1) (p<0.05). These results suggested that ECT2 has an important role in OSCC development and progression. However, little is known about the mechanism of ECT2 in OSCC progression. To determine whether ECT2 function is relevant to OSCC progression, we performed the shECT2 experiment and found that cellular proliferation decreased significantly as a result of cell cycle arrest at the G1 phase in ECT2 knockdown cells with up-regulation of p21cip1 and p27kip1 and down-regulation of cyclin D1, cyclin E, and CDK4, indicating that ECT2 function is related closely to OSCC progression.

GEFs, including ECT2, catalyze the exchange of GDP for GTP, thereby activating the Rho GTPases in signal transduction [7], [8], [9], [10], [11]. Activated Rho GTPases bind to and activate several downstream effectors, leading to multiple biologic processes, such as cellular size, cell cycle progression, apoptosis, survival, morphology, cellular polarity, cellular adhesion, and membrane trafficking [20], [21]. Up-regulation of Rho GTPase activity, often associated with tumorigenesis [22], has been detected in several human tumors, including pancreatic cancer, breast cancer, melanoma, lung cancer, colorectal cancer, and gastric cancer [12], [23]. On the other hand, Rho GTPases play a major role in promoting G1-S progression through modulation of cyclin and cyclin dependent kinase inhibitors (CDKIs) [24], [25]. Yamamoto et al. reported that when Rho GTPase was inhibited by the Clostridium botulinum C3 toxin or a dominant negative mutant, G1-S cell cycle progression was significantly impaired [26]. The impaired activation of GTPases is associated with constitutively elevated levels of p21cip1 and p27kip1, causing cells to accumulate in the G1 phase [27], [28], [29], [30], [31], [32]. We speculated that ECT2 knockdown leads to impaired activation of Rho GTPase, and consistent with that, we found not only up-regulation of the Cip/Kip family (p21cip1 and p27kip1) but also down-regulation of cyclin D1, cyclin E, and CDK4, leading to cell cycle arrest at the G1 phase, in ECT2 knockdown cells.

Cyclin D1, cyclin E, and CDK4 are also a critical regulator of G1 progression and G1-S transition. Inhibition of cyclin D1, cyclin E, and CDK4 expression blocks G1-S transition in the cell cycle [33], [34], [35], [36]. Cyclins D1–D3 and E families and their respective kinase partners, CDK4/6 and CDK2, are responsible for regulating the transition from G1 to S phase. The activities of the cyclin-CDK complexes are modulated by two types of CDKIs, Cip/Kip (p21Cip1, p27Kip1, and p57Kip2) and the INK4 (p15INK4B, p16INK4A, p18INK4C, and p19INK4D) families, both of which regulate cell cycle progression [37]. Members of the Cip/Kip family bind to cyclin-CDK complexes and inhibit their activities, which leads to reduced phosphorylated retinoblastoma protein and G1 cell cycle arrest.

In conclusion, our results indicated that ECT2 is overexpressed frequently in OSCC. Furthermore, ECT2 knockdown inhibited cellular proliferation in vitro by arresting cell cycle progression at the G1 phase by modulating expression of cell cycle-related molecules, which ultimately leads to inhibition of cyclin D1-CDK complex activity. These data suggested that ECT2 plays an important role in OSCC cell proliferation. ECT2 expression is likely to be a biomarker of proliferation and a potential therapeutic target for development of anticancer drugs in primary OSCCs.

Materials and Methods

Ethics Statement

All patients provided informed consent for a protocol reviewed and approved by the institutional review board of Chiba University. The written informed consents were obtained from all patients.

OSCC-derived cell lines and tissue specimens

HSC-2, HSC-3, HSC-4, and Ca9-22 cell lines, derived from human OSCCs, were purchased from the Human Science Research Resources Bank (Osaka, Japan). H1 and Sa3 cell lines were kindly provided by Dr. S. Fujita at Wakayama Medical University (Wakayama, Japan). Primary cultured HNOKs were obtained from three healthy donors [38], [39]. All cells were grown in Dulbecco's modified Eagle medium/F-12 HAM (Sigma-Aldrich Co, St. Louis, MO) supplemented with 10% fetal bovine serum (Sigma) and 50 units/ml penicillin and streptomycin (Sigma).

Tissue samples from 96 unrelated Japanese patients with primary OSCC who were treated at the Chiba University Hospital were obtained during surgical resection. The resected tissues were divided into two parts, one of which was frozen immediately and stored at −80°C until RNA isolation, and the second of which was fixed in 10% buffered formaldehyde solution for pathologic diagnosis and IHC. Histopathologic analysis of the tissues was performed according to the World Health Organization criteria by the Department of Pathology, Chiba University Hospital. Clinicopathologic staging was determined by the TNM classification of the International Union against Cancer. All patients had OSCC that was histologically confirmed, and tumor samples were checked to ensure that tumor tissue was present in more than 90% of the specimen.

Preparation of cDNA

Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. cDNA was generated from 5 µg of total RNA using Ready-To-Go You-Prime First-Strand Beads (GE Healthcare, Buckinghamshire, UK) and oligo (dT) primer (Sigma Genosys, Ishikari, Japan), according to the manufacturer's instructions.

mRNA expression analysis

Real-time qRT-PCR was performed to evaluate the expression levels of target genes (ECT2, p16INK4A, p21cip1, p27kip1, cyclin D1, cyclin E, and CDK4) in OSCC-derived cells and primary OSCCs. qRT-PCR was carried out with one method using a LightCycler FastStart DNA Master SYBR Green 1 Kit (Roche Diagnostics GmbH, Mannheim, Germany). The following primers were used: ECT2, forward 5′-ATTTTCATGTCGCCCGTTGT-3′ and reverse 5′-CCCATGTGATGGACCAATGTC-3′; p16INK4A, forward 5′-CAGACATCCCCGATTGAAAGAAC-3′ and reverse 5′-GGTAGTGGGGGAAGGCATATATCT-3′; p21cip1, forward 5′-CCCAGTTCATTGCACTTTGATTAGC-3′and reverse 5′-CAGTCTAGGTGGAGAAACGGGAAC-3′; p27kip1, forward 5′-CCGGCTAACTCTGAGGACAC-3′and reverse 5′-AGAAGAATCGTCGGTTGCAG-3′; cyclin D1, forward 5′-GCATGTTCGTGGCCTCTAAGA-3′and reverse 5′-CGGTGTAGATGCACAGCTTCTC-3′; cyclin E, forward 5′-TTCTTGAGCAACACCCTCTTCTGCAGCC-3′and reverse 5′-TCGCCATATACCGGTCAAAGAAATCTTGTGCC-3′; CDK4, forward 5′-TGCAACACCTGTGGACATGTG-3′and reverse 5′-ATTTTGCCCAACTGGTCGG-3′. Amplified products were analyzed by 3% agarose gel electrophoresis to ascertain size and purity. The PCR reactions using the LightCycler apparatus were performed in a final volume of 20 µl of a reaction mixture consisting of 2 µl of FirstStart DNA Master SYBR Green I mix, 3 mM MgCl2, and l µM of the primers, according to the manufacturer's instructions. The reaction mixture was loaded into glass capillary tubes and subjected to an initial denaturation at 95°C for 10 min, followed by 45 rounds of amplification at 95°C (10 sec) for denaturation, 62°C (10 sec) for annealing, and 72°C (10 sec) for extension, with a temperature slope of 20°C/sec. The transcript amounts for the target genes were estimated from the respective standard curves and normalized to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (forward 5′-CATCTCTGCCCCCTCTGCTGA-3′and reverse 5′-GGATGACCTTGCCCACAGCCT-3′) transcript amount determined in corresponding samples.

Protein extraction

The cells were washed twice with cold phosphate-buffered saline (PBS) and centrifuged briefly. The cell pellets were incubated at 4°C for 30 min in a lysis buffer (7 M urea, 2 M thiourea, 4% w/v CHAPS, and 10 mM Tris pH 7.4) with proteinase inhibitor cocktail (Roche). The protein concentration was measured with BCA Protein Assay Kit (Thermo, Rockford, IL).

Western blot analysis

Protein extracts were electrophoresed on 4–12% Bis-Tris gel, transferred to nitrocellulose membranes (Invitrogen), and blocked for 1 h at room temperature in Blocking One (Nacalai tesque, Kyoto, Japan). The membranes were washed three times with 0.1% Tween 20 in Tris-buffered saline and incubated with 2 µg/ml affinity-purified rabbit anti-human ECT2 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. The membranes were washed again and incubated with a 1[ratio]10,000 of goat anti-rabbit IgG (H+L) HRP conjugate (Promega, Madison, WI) as a secondary antibody for 2 h at room temperature. Finally, the membranes were detected using SuperSignal West Pico Chemiluminescent substrate (Thermo) and immunoblotting was visualized by exposing the membranes to ATTO Light-Capture II (ATTO, Tokyo, Japan). Signal intensities were quantitated using the CS Analyzer version 3.0 software (ATTO).

Transfection

OSCC cell lines (Sa3 and H1) were stably transfected with the ECT2 shRNA (shECT2) or the control shRNA (Mock) (Santa Cruz Biotechnology) construct by Lipofectamine LTX and Plus Reagents (Invitrogen). After transfection, the cells stably shECT2 were isolated by the culture medium containing 2 µg/mL puromycin (Invitrogen). 2–3 weeks after transfection, viable colonies were picked up and transferred to new dishes. shECT2- and Mock-transfected cells were used for further experiments.

IHC

IHC of 4-µm sections of paraffin-embedded specimens was performed using rabbit anti-ECT2 polyclonal antibody (Santa Cruz Biotechnology). Briefly, after deparaffinization and hydration, the endogenous peroxidase activity was quenched by 30-min incubation in a mixture of 0.3% hydrogen peroxide solution in 100% methanol, after which the sections were blocked for 2 h at room temperature with 1.5% blocking serum (Santa Cruz Biotechnology) in PBS before reaction with anti-ECT2 antibody (1[ratio]100 dilution) at 4°C in a moist chamber overnight. Upon incubation with the primary antibody, the specimens were washed three times in PBS and treated with Envision reagent (DAKO, Carpinteria, CA) followed by color development in 3,3′-diaminobenzidine tetrahydrochloride (DAKO). The slides then were lightly counterstained with hematoxylin, dehydrated with ethanol, cleaned with xylene, and mounted. Non-specific binding of an antibody to proteins other than the antigen sometimes occurred. To avoid non-specific binding, an immunizing peptide blocking experiment was performed. As a negative control, triplicate sections were immunostained without exposure to primary antibodies, which confirmed the staining specificity. To quantify the state of ECT2 protein expression in those components, we used IHC score systems described previously [6], [39], [40], [41], [42], [43], [44], [45], [46], [47]. Briefly, the stained cells were determined in at least five random fields at 400× magnification in each section. The intensity of the ECT2 immunoreaction in the cell was scored as follows: 1+, weak; 2+, moderate; and 3+, intense. The cell number and the staining intensity then were multiplied to produce an ECT2 IHC score. Cases with a score exceeding 85.33 (the highest score for normal tissue) were defined as ECT2-positive. Two independent pathologists, both of whom were masked to the patients' clinical status, made these judgments.

Cellular proliferation

To investigate the effect of shECT2 on cellular proliferation, shECT2- and Mock-transfected cells were seeded in 6-well plates at a density of 1×104 viable cells per well. At the indicated time points, the cells were trypsinized and counted using a hemocytometer in triplicate.

Cell cycle analysis

To determine cell cycle distribution, the cells were harvested, washed with PBS, and probed with CycleTEST Plus DNA reagent kit (Becton-Dickinson, San Jose, CA), according to the manufacturer's protocol. Briefly, the cells concentrated to 5.0×105 cells/ml were centrifuged at 400×g for 5 min at room temperature. Then we added 250 µl of Solution A (trypsin buffer) to the tube and gently mixed. We allowed the trypsin to react for 10 min at room temperature. Next, we added 200 µl of Solution B (trypsin inhibitor and RNase in a buffer) and gently mix. We incubated with the mixture for 10 min at room temperature. Finally, we added 200 µl of Solution C (propidium iodide stain solution). And we gently mixed as above and incubate for 10 min in the dark on ice. Flow cytometric determination of DNA content was analyzed by a FACScalibur (Becton-Dickinson). The fractions of the cells in the G0–G1, S, and G2–M phases were analyzed using Flow Jo software (Tree Star, Ashland, OR).

Statistical analysis

The statistical significance of the ECT2 expression levels was evaluated using Fisher's exact test or Mann-Whitney U test. P<0.05 was considered statistically significant. The data are expressed as the mean ± SEM.

Acknowledgments

We thank Lynda C. Charters for editing this manuscript, and Drs. Hiroshi Nakajima and Hiroaki Takatori, Department of Molecular Genetics, Graduate School of Medicine, Chiba University, for helpful discussions and critical review of the manuscript.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This study was supported by a Grant-in-Aid Scientific Research (No. 20592353) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Sudbo J, Reith A. The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. Int J Cancer. 2005;115:339–345. [PubMed]
2. Mashberg A, Boffetta P, Winkelman R, Garfinkel L. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer. 1993;72:1369–1375. [PubMed]
3. Macfarlane GJ, Zheng T, Marshall JR, Boffetta P, Niu S, et al. Alcohol, tobacco, diet and the risk of oral cancer: A pooled analysis of three case-control studies. European Journal of Cancer Part B: Oral Oncology. 1995;31:181–187. [PubMed]
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767. [PubMed]
5. Marshall CJ. Tumor suppressor genes. Cell. 1991;64:313–326. [PubMed]
6. Yamano Y, Uzawa K, Shinozuka K, Fushimi K, Ishigami T, et al. Hyaluronan-mediated motility: A target in oral squamous cell carcinoma. Int J Oncol. 2008;32:1001–1009. [PubMed]
7. Tatsumoto T, Xie X, Blumenthal R, Okamoto I, Miki T. Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis. J Cell Biol. 1999;147:921–928. [PMC free article] [PubMed]
8. Kim JE, Billadeau DD, Chen J. The tandem BRCT domains of Ect2 are required for both negative and positive regulation of Ect2 in cytokinesis. J Biol Chem. 2005;280:5733–5739. [PubMed]
9. Niiya F, Xie X, Lee KS, Inoue H, Miki T. Inhibition of cyclindependent kinase 1 induces cytokinesis without chromosome segregation in an ECT2 and MgcRacGAP-dependent manner. J Biol Chem. 2005;280:36502–36509. [PubMed]
10. Niiya F, Tatsumoto T, Lee KS, Miki T. Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA. Oncogene. 2006;25:827–837. [PubMed]
11. Hara T, Abe M, Inoue H, Yu LR, Veenstra TD, et al. Cytokinesis regulator ECT2 changes its conformation through phosphorylation at Thr-341 in G2/M phase. Oncogene. 2006;25:566–578. [PubMed]
12. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C, Lacal JC. Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays. 2005;27:602–613. [PubMed]
13. Salhia B, Tran NL, Chan A, Wolf A, Nakada M, et al. The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. Am J Pathol. 2008;173:1828–1838. [PubMed]
14. Sano M, Genkai N, Yajima N, Tsuchiya N, Homma J, et al. Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients. Oncol Rep. 2006;16:1093–1098. [PubMed]
15. Justilien V, Fields AP. Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation. Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation. Oncogene. 2009;28:3597–3607. [PMC free article] [PubMed]
16. Saito S, Liu XF, Kamijo K, Raziuddin R, Tatsumoto T, et al. Deregulation and mislocalization of the cytokinesis regulator ECT2 activate the Rho signaling pathways leading to malignant transformation. J Biol Chem. 2004;279:7169–7179. [PubMed]
17. Zhang ML, Lu S, Zhou L, Zheng SS. Correlation between ECT2 gene expression and methylation change of ECT2 promoter region in pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2008;7:533–538. [PubMed]
18. Yang YL, Chu JY, Luo ML, Wu YP, Zhang Y, et al. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer. 2008;Feb: 47(2):127–36. [PubMed]
19. Hussenet T, Dali S, Exinger J, Monga B, Jost B, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010;Jan 29: 5(1):e8960. [PMC free article] [PubMed]
20. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629–635. [PubMed]
21. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol. 2001;11:471–477. [PubMed]
22. Boettner B, Van Aelst L. The role of Rho GTPases in disease development. Gene. 2002;286:155–174. [PubMed]
23. Pan Y, Bi F, Liu N, Xue Y, Yao X, et al. Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun. 2004;315:686–691. [PubMed]
24. Coleman ML, Marshall CJ, Olson MF. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol. 2004;5:355–366. [PubMed]
25. Villalonga P, Ridley AJ. Rho GTPases and cell cycle control. Growth Factors. 2006;24:159–164. [PubMed]
26. Yamamoto M, Marui N, Sakai T, Morii N, Kozaki S, et al. ADP-ribosylation of the rhoA gene product by botulinum C3 exoenzyme causes Swiss 3T3 cells to accumulate in the G1 phase of the cell cycle. Oncogene. 1993;8:1449–1455. [PubMed]
27. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995;269:1270–1272. [PubMed]
28. Olson MF, Paterson HF, Marshall CJ. Signals from ras and rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature. 1998;394:295–299. [PubMed]
29. Coleman ML, Densham RM, Croft DR, Olson MF. Stability of p21Waf1/Cip1 CDK inhibitor protein is responsive to RhoA-mediated regulation of the actin cytoskeleton. Oncogene. 2006;25:2708–2716. [PubMed]
30. Croft DR, Olson MF. The rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol. 2006;26:4612–4627. [PMC free article] [PubMed]
31. Coleman ML, Marshall CJ, Olson MF. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome mediated degradation. EMBO J. 2003;22:2036–46. [PubMed]
32. McFarlane C, Kelvin AA, de la Vega M, Govender U, Scott CJ, et al. The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. Cancer Res. 2010;70:3329–3339. [PubMed]
33. Quelle DE, Ashmun RA, Shurtleff SA, Kato J, Bar-Sagi D, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993;7:1559–1571. [PubMed]
34. Musgrove EA, Lee CSL, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A. 1994;91:8022–8026. [PubMed]
35. Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with cdk4 is required for cyclin D1 function in G1 progression. Oncogene. 1994;9:2663–2674. [PubMed]
36. Yong Liu, Wen Li, Caisheng Ye, Ying Lin, Tuck-Yun Cheang, et al. Gambogic Acid Induces G0/G1 Cell Cycle Arrest and Cell Migration Inhibition Via Suppressing PDGF Receptor βTytosine Phosphorylation and Rac1 Activity in Rat Aortic Smooth Muscle Cells. J Atheroscler Thromb. 2010;Jun 11 [PubMed]
37. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–1512. [PubMed]
38. Kasamatsu A, Uzawa K, Nakashima D, Koike H, Shiiba M, et al. Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int J Mol Med. 2005;16:269–273. [PubMed]
39. Endo Y, Uzawa K, Mochida Y, Shiiba M, Bukawa H, et al. Sarcoendoplasmic reticulum Ca2+ ATPase type 2 downregulated in human oral squamous cell carcinoma. Int J Cancer. 2004;110:225–231. [PubMed]
40. Shimada K, Uzawa K, Kato M, Endo Y, Shiiba M, et al. Aberrant expression of RAB1A in human tongue cancer. Br J Cancer. 2005;92:1915–1921. [PMC free article] [PubMed]
41. Saito K, Uzawa K, Endo Y, Kato Y, Nakashima D, et al. Plasma membrane Ca2+ ATPase isoform 1 down-regulated in human oral cancer. Oncol Rep. 2006;15:49–55. [PubMed]
42. Onda T, Uzawa K, Endo Y, Bukawa H, Yokoe H, et al. Ubiquitous mitochondrial creatine kinase downregulated in oral squamous cell carcinoma. Br J Cancer. 2006;94:698–709. [PMC free article] [PubMed]
43. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, et al. Overexpression of stathmin in oral squamous-cell carcinoma: Correlation with tumour progression and poor prognosis. Br J Cancer. 2006;94:717–723. [PMC free article] [PubMed]
44. Kato Y, Uzawa K, Yamamoto N, Kouzu Y, Koike H, et al. Overexpression of Septin1: Possible contribution to the development of oral cancer. Int J Oncol. 2007;31:1021–1028. [PubMed]
45. Nomura H, Uzawa K, Yamano Y, Fushimi K, Ishigami T, et al. Overexpression and altered subcellular localization of autophagy-related 16-like 1 in human oral squamous-cell carcinoma: Correlation with lymphovascular invasion and lymph-node metastasis. Hum Pathol. 2009;40:83–91. [PubMed]
46. Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol. 2006;29:117–124. [PubMed]
47. Tanaka C, Uzawa K, Shibahara T, Yokoe H, Noma H, et al. Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J Dent Res. 2003;82:607–611. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science